Egalet Corp (EGLT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Egalet Corp (EGLT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH7967D
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Egalet Corp (Egalet) formerly BM Research A/S, focuses on the development and commercialization of medicines for patients with moderate to severe pain. Its product portfolio includes OXAYDO tablets for oral use for the management of acute and chronic moderate to severe pain and SPRIX nasal spray, a potent non-steroidal anti-inflammatory drug (NSAID). The company uses its proprietary drug delivery platform technology Egalet Guardian, an abuse-deterrent formulation for the treatment of pain and other indications. Egalet's other pipeline products include Arymo, Egalet-001, Egalet-002 and Egalet-003. The company partners with pharmaceutical and biotechnology companies in the initial phase of clinical testing. It operates through its office in the US and a research, development and manufacturing facility located in Denmark. Egalet is headquartered in Wayne, Pennsylvania, the US.

Egalet Corp (EGLT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Egalet Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Egalet Corp, Medical Devices Deals, 2011 to YTD 2017 10

Egalet Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Egalet Corp, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 12

Venture Financing 13

Egalet Raises USD15 Million in Venture Debt Financing 13

Egalet Raises US$10 Million In Initial Closing Of Venture Financing 14

Egalet Raises US$14.3 Million In Series B2 Financing 15

Egalet Secures Venture Funding 16

Partnerships 17

Egalet Enters into Co-Marketing Agreement with Septodont for SPRIX Nasal Spray 17

Egalet Enters into Agreement with Teva Pharma 17

Licensing Agreements 18

Egalet Enters into Licensing Agreement with Acura Pharma 18

Equity Offering 19

Egalet Raises USD86.3 Million in Public Offering of Shares 19

Egalet Completes IPO For US$58 Million 21

Egalet Completes Private Placement Of Shares For US$15 Million 22

Debt Offering 23

Egalet Raises USD40 Million in Second Tranche of Private Placement of 13% Notes 23

Egalet Raises USD40 Million in First Tranche of Private Placement of 13% Notes 24

Egalet Raises USD60 Million in Private Placement of Notes Due 2020 25

Egalet Corp-Key Competitors 27

Key Employees 28

Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Mar 09, 2017: Egalet Reports Fourth Quarter and Full Year 2016 Financial Results 30

Nov 04, 2016: Egalet Reports Third Quarter 2016 Financial Results 31

Aug 04, 2016: Egalet Reports Second Quarter 2016 Financial Results 32

May 10, 2016: Egalet Reports First Quarter 2016 Financial Results 33

Mar 08, 2016: Egalet Reports Fourth Quarter and Full Year 2015 Financial Results 34

Corporate Communications 35

Apr 10, 2017: Egalet Announces Changes to Board of Directors 35

Dec 08, 2016: Egalet appoints new board member 36

Product News 37

12/16/2016: Egalet Announces Positive Top-Line Results from an Intranasal Human Abuse Potential Study of Egalet-002 37

03/24/2016: Egalet Announces ALERRT Study Demonstrated Egalet-002 Required Significantly More Effort to Manipulate than OxyContin 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40

List of Figures

Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Egalet Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Egalet Corp, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Egalet Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Egalet Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Egalet Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Egalet Corp, Deals By Therapy Area, 2011 to YTD 2017 9

Egalet Corp, Medical Devices Deals, 2011 to YTD 2017 10

Egalet Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 12

Egalet Raises USD15 Million in Venture Debt Financing 13

Egalet Raises US$10 Million In Initial Closing Of Venture Financing 14

Egalet Raises US$14.3 Million In Series B2 Financing 15

Egalet Secures Venture Funding 16

Egalet Enters into Co-Marketing Agreement with Septodont for SPRIX Nasal Spray 17

Egalet Enters into Agreement with Teva Pharma 17

Egalet Enters into Licensing Agreement with Acura Pharma 18

Egalet Raises USD86.3 Million in Public Offering of Shares 19

Egalet Completes IPO For US$58 Million 21

Egalet Completes Private Placement Of Shares For US$15 Million 22

Egalet Raises USD40 Million in Second Tranche of Private Placement of 13% Notes 23

Egalet Raises USD40 Million in First Tranche of Private Placement of 13% Notes 24

Egalet Raises USD60 Million in Private Placement of Notes Due 2020 25

Egalet Corp, Key Competitors 27

Egalet Corp, Key Employees 28

Egalet Corp, Other Locations 29

Egalet Corp, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Egalet Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16863
Site License
USD 500 INR 33725
Corporate User License
USD 750 INR 50588

NEWSLETTER BY CATEGORY




Testimonials

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com